TransMedics Group, Inc. (NASDAQ:TMDX) Given Average Rating of “Moderate Buy” by Brokerages

TransMedics Group, Inc. (NASDAQ:TMDX) has been given a consensus rating of “Moderate Buy” by the eleven research firms that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $122.70.

Several brokerages have issued reports on TMDX. JPMorgan Chase & Co. reaffirmed a “neutral” rating and set a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $104.00 price target on shares of TransMedics Group in a research report on Tuesday, March 11th. Piper Sandler reduced their price objective on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Robert W. Baird lowered their target price on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Wednesday, March 26th.

Hedge Funds Weigh In On TransMedics Group

A number of large investors have recently bought and sold shares of the company. Arizona State Retirement System boosted its holdings in shares of TransMedics Group by 1.9% in the fourth quarter. Arizona State Retirement System now owns 9,668 shares of the company’s stock valued at $603,000 after acquiring an additional 184 shares in the last quarter. National Bank of Canada FI boosted its holdings in TransMedics Group by 174.7% in the 3rd quarter. National Bank of Canada FI now owns 412 shares of the company’s stock valued at $65,000 after purchasing an additional 262 shares in the last quarter. Quarry LP increased its position in TransMedics Group by 557.1% during the 3rd quarter. Quarry LP now owns 368 shares of the company’s stock worth $58,000 after purchasing an additional 312 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in TransMedics Group by 7.2% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 4,721 shares of the company’s stock worth $294,000 after purchasing an additional 317 shares during the period. Finally, Park Avenue Securities LLC lifted its holdings in shares of TransMedics Group by 3.8% in the 4th quarter. Park Avenue Securities LLC now owns 8,797 shares of the company’s stock valued at $548,000 after buying an additional 322 shares during the period. Hedge funds and other institutional investors own 99.67% of the company’s stock.

TransMedics Group Trading Up 7.1 %

NASDAQ TMDX opened at $73.11 on Thursday. The firm’s fifty day moving average price is $69.76 and its 200 day moving average price is $86.43. TransMedics Group has a 12 month low of $55.00 and a 12 month high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The company has a market capitalization of $2.46 billion, a price-to-earnings ratio of 77.78 and a beta of 2.12.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.